Creative Medical Technology Holdings Inc (CELZ) USD0.001

Sell:$2.50Buy:$2.55$0.13 (5.11%)

Prices delayed by at least 15 minutes
Sell:$2.50
Buy:$2.55
Change:$0.13 (5.11%)
Deal now
Prices delayed by at least 15 minutes
Sell:$2.50
Buy:$2.55
Change:$0.13 (5.11%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.

Key people

Timothy Warbington
President, Chief Executive Officer, Director
Donald Dickerson
Chief Financial Officer, Senior Vice President, Director
Michael H. Finger
Independent Director
Susan Hegarty Snow
Independent Director
Bruce S. Urdang
Independent Director
Click to see more

Key facts

  • EPIC
    CELZ
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US22529Y4089
  • Market cap
    $7.52m
  • Employees
    4
  • Shares in issue
    2.59m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.